EP Patent

EP4545544A3 — Modified crispr rna and modified single crispr rna and uses thereof

Assigned to Ionis Pharmaceuticals Inc · Expires 2025-10-08 · 1y expired

What this patent protects

The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of erRNA. In cetain embodiments, such modified oligonucleotides provide improved properties of scrR…

USPTO Abstract

The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of erRNA. In cetain embodiments, such modified oligonucleotides provide improved properties of scrRNA.

Drugs covered by this patent

Patent Metadata

Patent number
EP4545544A3
Jurisdiction
EP
Classification
—
Expires
2025-10-08
Drug substance claim
No
Drug product claim
No
Assignee
Ionis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.